LYEL compared with VIR: revenue, margins and what each company keeps, and the suppliers and customers both name

LYELLyell Immunopharma, Inc.

Mkt capRevenueRevenue

VIRVir Biotechnology, Inc.

Mkt capRevenueRevenue

Compare

LYELLyell Immunopharma, Inc.

VIRVir Biotechnology, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LYEL 11

—City of Hope Comprehensive Cancer Centerunlistedsupplier

—Dana Farber Cancer Instituteunlistedsupplier

—Innovative Cellular Therapeutics Holdings Limited and Innovative Cellular Therapeutics, Inc. (together, ICT)unlistedsupplier

—Miltenyi CliniMACS PRODIGY ®unlistedsupplier

7 more · LYEL chain ›

Shared 0

No shared counterparties.

Only VIR 8

ALNYAlnylamsupplier

XNCRXencorsupplier

SNYSanofisupplier

—Astellasunlisted

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

customer

4 more · VIR chain ›

LYELLyell Immunopharma, Inc.

14.85▼−1.03%· post 14.85

Mkt cap$365.3MRevenue$3,000Q3 FY26Revenue$36,000FY25

VIRVir Biotechnology, Inc.

12.20▲+10.71%· post 12.30

ClosedNov 6 '26

Mkt cap$1.9BRevenue$239MQ2 FY26Revenue$74MFY24

Compare

ClosedNov 6 '26

LYELLyell Immunopharma, Inc.

VIRVir Biotechnology, Inc.

14.85▼−1.03%post 14.85

Price

12.20▲+10.71%post 12.30

$365.3M

Mkt cap

$1.9B

Q3 FY26$3,000

Revenue

$239MQ2 FY26

FY25$36,000

Revenue

$74MFY24

LYEL14.85▼−1.03%vsVIR12.20▲+10.71%ClosedNov 6 '26